BLACK WEEKSViale −15 % · kompleti −10 % · ostalo −5 %s kodoBrezplačna dostava v Nemčiji od 200 €

Ta stran je bila prevedena samodejno in lahko vsebuje napake. Ste materni govorec? Veseli bomo vaših povratnih informacij in popravkov.Pošljite povratne informacije

The Peptide Desk The Peptide Desk
Cerebrolysin, fotografija izdelka
Cognition

Cerebrolysin

Cognition

  • Odprema iz Nemčije

Naročilo

Cena na kos - Brezplačna dostava v Nemčiji od 200 € med Black Weeks
  • DHL s sledenjem
  • Diskretna embalaža

4.6 od 5 na Trustpilotu73 ocen

Na prvi pogled

Cerebrolysin v številkah

Ključni podatki iz našega leksikona.

Celoten vnos v leksikonu
Class
Neurotrophic peptide mixturebrain extract
Form
Lyophilisate, 60mg/vial6-pack = 360mg
Sizes
60mg/6vials1 size in the shop
  1. Randomized study in acute ischemic stroke (CASTA) (opens in a new tab)

    Heiss et al., Stroke, 2012
  2. Cochrane review on vascular dementia (opens in a new tab)

    Cui et al., Cochrane Database of Systematic Reviews, 2019

Znanje

Vse o Cerebrolysin

Priporočljivo zraven

Kaj potrebujete zraven

Bakteriostatska voda se samodejno doda v vašo košarico. Brizge in robčki z enim klikom.

Inzulinske brizge

10 kos. · 5.50 €

Alkoholni robčki

50 kos. · 10 €

Koliko vode?

Enote na brizgi za vašo velikost viale.

Odpri kalkulator →

FAQ

Pogosta vprašanja

Viri za vsak odgovor: vnos v leksikonu

Imate še vprašanje?

Pišite nam, naša ekipa vam bo pomagala.

Is Cerebrolysin approved?

A Cochrane review describes Cerebrolysin as widely used for stroke in Russia, Eastern Europe, China and other Asian countries. Many of the manufacturer's trials are registered as phase 4. This powder is a research product, the trials used the ready-made liquid solution.

What is in Cerebrolysin?

A mixture made in a standardised process from small peptides under 10 kDa and free amino acids from pig brain. It has no single receptor but is meant to act like the body's own nerve growth factors.

What did the large stroke trial CASTA show?

1,070 people with acute stroke received Cerebrolysin or saline for 10 days. There was no difference on the primary endpoint. In severely affected patients a post hoc analysis showed 10.5 percent deaths with Cerebrolysin and 20.2 percent with placebo. The authors see this as a signal that still needs confirmation.

What is known in vascular dementia?

A Cochrane review with six trials and 597 participants found a benefit for thinking and overall condition. The evidence is very low certainty though, the trials are at high risk of bias and, where known, were supported by the manufacturer. The authors think the effect may be too small to matter in daily life.

Does it help recovery after stroke or brain injury?

In the CARS trial with rehab over 21 days arm function after 90 days was clearly better than on placebo, but the trial was small and exploratory. After moderate to severe brain injury CAPTAIN II found a small to medium advantage across many measures. Both need to be confirmed in larger trials.

Which side effects are known?

In acute stroke Cerebrolysin changed neither mortality nor the number of all serious adverse events according to the Cochrane review, but non-fatal serious adverse events were more common than on placebo (relative risk 2.39). In an Alzheimer's trial agitation, dizziness and headache were common.

Do the trials transfer to this product?

Only to a limited extent. In the trials the ready-made liquid solution was given as an infusion into a vein, over some days to weeks. This product is a freeze-dried powder that the entry describes for subcutaneous or intramuscular use. There are no data on this form.

Sorodno

Sorodni izdelki